Please assess the completion status of the following clinical trial:

Trial Title: Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects are fully eligible for and have completed the AMYPRED-US (Amyloid Prediction in early stage Alzheimer's disease from acoustic and linguistic patterns of speech) study.~(See https://clinicaltrials.gov/ct2/show/NCT04928976)~- Subject consents to take part in FUTURE extension study.~Exclusion Criteria:~* Subject hasn't completed the full visit day in the AMYPRED-US study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1: MCI amyloid positive (Type: None): * Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's~* Positive amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)
- Arm 2: MCI amyloid negative (Type: None): * Non-AD Mild Cognitive Impairment (MCI)~* Negative amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)
- Arm 3: CN amyloid positive (Type: None): * Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Positive amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)
- Arm 4: CN amyloid negative (Type: None): * Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Negative amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)

Based on this trial design, predict the completion outcome and termination type (if applicable).